Urovant to receive ~$75M in up front, regulatory & sales milestones along with royalties. Both companies will share responsibility for vibegron clinical trials in the pediatric populations in the EU
Urovant also obtain full commercialization rights to vibegron in the US and other selected markets while Pierre Fabre will receive manufacturing services from Urovant. The companies collaborated to commercialize vibegron for OAB in the EEA, UK & Switzerland with option territories incl. french-speaking countries of SSA, Turkey & Eastern EU countries
This collaboration affirms Pierre Fabre’s expertise in urology & women’s health for 5 decades and the group’s aspirations to provide therapeutic treatments for chronic diseases
Ref: Bussinesswire | Image: Urovant Sciences
